Today, adipose tissue has ceased to be perceived only as an energetic substance with its intrinsic properties in the form of thermoregulation and mechanical protection, known since the beginning of the twentieth century. Today, adipose tissue is a fullfledged endocrine organ that is distributed throughout the body — the usefulness of its work directly affects the energy balance, not only through involvement in the metabolism of carbohydrates and fats, but also by the production of many adipokines, a total of more than 600 known today. This review research the causal relationship of subclinical or systemic inflammation of adipose tissue with an excess of energy resources, insulin resistance, leptin, adiponectin, estrogen metabolites and one of the most pro-inflammatory cytokines - interleukin 6. Attention is also paid to the relationship between prostate cancer and obesity, as an ambiguous relationship due to the maximum paying attention to testosterone. Further study of adipose tissue will make it possible to establish specific pathophysiological mechanisms responsible for the development of not only disorders of carbohydrate metabolism, but also a number of other systems in view of the not fully understood systemic action of adipokines and associated inflammatory mediators in obese individuals. Systematic literature search was perform in the Medline, Scopus, Web of Science and elibrary databases.
1 January 2020 in Endocrinology: News, Opinions, Training
Latent autoimmune diabetes in adults (LADA) according to various sources is from 4 to 12% of all cases of type 2 diabetes mellitus (T2DM). Its uniqueness lies in the simultaneous combination of autoantibodies to β-cells (characteristic of T1DM) and the possibility of treatment with oral hypoglycemic drugs (characteristic of T2DM) for at least 6 months. This is based on the pathogenesis common for T1DM and T2DM — the presence of an autoimmune reaction with the simultaneous involvement of adaptive and innate immunity, as well as, to a lesser extent, insulin resistance and a number of components of the metabolic syndrome. LADA has more in common with T1DM — the same stages in the development of the disease, from genetic predisposition to the undoubted development of insulin dependence, the difference lies in the duration of each of the periods and the age of manifestation. LADA is characterized by an older age of manifestation of 30–35 years and a slower rate of destruction of β-cells. This article presents data on the diagnosis, progress of LADA, its similarities and differences with other types of DM, and immunological features. The article also analyzes the modern approach to the treatment of patients with LADA and promising methods of treatment. The search for information was processing in published sources attached to the search engines PubMed, Google Scholar, Scopus, Web of Science, eLibrary.ru over the past 10 years. The following medical subject headings were used: latent autoimmune diabetes in adults, diabetes mellitus type 1 and 2, immunology, pancreas, genetic, treatment in various combinations using OR and AND logical operators.
1 January 2020 in Endocrinology: News, Opinions, Training
In modern diabetology, the most important condition for a personalized approach to patient management is to determine the type of diabetes mellitus. Particular attention is drawn to a large, but at the same time insufficiently studied group of patients with diabetes mellitus due to diseases of the pancreas or as a result of surgical interventions on the pancreas, in particular, patients who, for a number of vital indications, undergo total pancreatectomy and the mechanism of development of impaired glucose homeostasis have not been studied in these patients. To date, there are no specific algorithms for managing this category of patients. This clinical example emphasizes that the management of glycemia in patients with diabetes mellitus as a result of total pancreatectomy is an extremely difficult task that requires a multidisciplinary approach in the treatment of this category of patients, the participation of an endocrinologist at all stages of patient treatment.